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In a small sample of 57 retrovirus integration sites (RISs) isolated from 23 end-stage lymphomas induced in NMRI mice by the B-
lymphotropic Akv wt or an enhancer mutant hereof, Akv1–99, we identified 14 novel RISs and defined 9 novel CISs (common insertion sites).
Moreover, when comparing with RISs from tumors induced by the T-lymphomagenic SL3-3, we observed that SL3-3 targets RefSeq promoter
regions with a significantly higher frequency than Akv/Akv1–99 and in an orientation-dependent way. Altogether, our results strongly emphasize
the importance of host genetic background and virus type for retroviral insertion mutagenesis screens and suggest that different types of MLV may
favor specific genomic regions and orientations in order exert optimal effect on target gene expression during lymphoma induction and
development.
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Tumor induction by the non-acute-transforming retroviruses
is a multistep process in which insertional mutagenesis plays a
fundamental role and where the effect of the individual integ-
rated provirus will depend on the particular location of the
insertion site relative to the targeted gene. The integrated pro-
virus may affect the neighboring genes in a variety of ways by
what have been described as promoter insertion, enhancer in-
sertion, and/or truncation of a normal cellular gene (Rosenberg
and Jolicoeur, 1997; Uren et al., 2005).
In the era of post-genome-sequence completion, retroviral
insertional mutagenesis in mice has proven its significance as a
potent instrument to identify candidate cancer genes, in par-
ticular, those related to diseases in the hematopoietic system
(Erkeland et al., 2004; Hansen et al., 2000; Joosten et al., 2002;
Kim et al., 2003; Li et al., 1999; Mikkers et al., 2002; Sorensen
et al., 1996). Several independent screening studies have thus⁎ Corresponding author. Fax: +45 8619 6500.
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proviral insertions, and much of the published collection of
miscellaneous retrovirus integration sites (RISs) has been
organized in the Retroviral Tagged Cancer Gene Database
(RTCGD; http://RTCGD.ncifcrf.gov; Akagi et al., 2004). For
the present, this database (version mm6) contains more than
2200 insertions, which define more than 350 common integ-
ration sites (CISs).
Evidently, the strength of combining RISs from many
different sources lies in the opportunity of discovering novel
rare CISs and improving the resolution of already known
CISs. However, this also precludes detailed and faithful
comparison studies between different model systems since
several parameters will differ between the various studies;
parameters of which the most influencing ones would be
different host genetic backgrounds, different virus strains, and
different PCR-based strategies for tag identification. As an
example, we have in a previous study examined the integ-
ration site pattern around the Fos/Jdp2/Batf locus in tumors
induced by SL3-3 or Akv murine leukemia viruses (MLVs) in
NMRI or SWR genetic background (Rasmussen et al., 2005),
and we noted a clear difference from the pattern within the
194 J. Martín-Hernández et al. / Virology 353 (2006) 193–199same locus observed by Hwang et al. (2002), whose studies
were based upon Moloney MLV-induced tumors in p27+/+ or
p27−/− C57/B6J×129/Sv hybrid mice. Due to usage of
different mouse strains, different viruses, and different PCR-
based methods, it was not possible to determine whether host
genetic composition and/or inherent viral features were the
main contributor to the observed differences. To clarify such
issues, equivalent experimental setups are needed.
Here, we report on the analysis of provirus integration sites
from three comparable studies, where the mouse strain and the
PCR method for tag identification are unchanged. We observe
that in end-stage lymphomas the T-lymphomagenic SL3-3 MLV
is found much more frequently in promoter regions than the B-
lymphomagenic Akv and Akv1–99 MLVs. Likewise, we see a
significant lack of Akv1–99 insertions downstream of the target
gene compared to Akv wt. Due to the comparable experimental
setups, the observed differences in integration site pattern in
end-stage tumors can be associated with virus characteristics
rather than mouse genetic background or PCR strategy. More-
over, by using this particular combination of mouse strain, virus
types, and PCR method, we identify 14 novel RISs and define 9
novel CISs.Results and discussion
Integration site analyses of Akv- and Akv1–99-induced tumors
Akv1–99 is an ecotropic MLV derived from Akv MLV by
deletion of one copy of the 2 × 99-bp transcriptional enhancer in
the proviral LTR (Fig. 1). Both viruses induce B-cell lympho-
mas with nearly 100% incidence in randomly bred NMRI mice
and with a mean latency period of about 12 months (Lovmand
et al., 1998). By a simple two-step PCR method, which has
previously been described as an efficient technique for the iso-
lation and sequencing of provirus–host junctions (Martin-
Hernandez et al., 2001; Sorensen et al.,1993, 1996), we have
from 23 Akv-wt- and Akv1–99-induced tumors from an earlier
study (Lovmand et al., 1998) amplified a total of 57 proviralFig. 1. Genomic structures of Akv, Akv1–99, and SL3-3 proviruses. Akv MLV con
contains only one copy of this 99 bp sequence. The SL3-3 LTR contains different U3 e
each virus name, tumor phenotype and average latency period in randomly bred
sequences. FP = flanking primer, which is constructed and specific for each integraflanking sequences, representing 28 tags from 10 Akv-wt-
induced tumors and 29 tags from 13 Akv1–99-induced tumors.
Of these, 24 and 26 tags, respectively, could be located within
±100 kb of a RefSeq (Maglott et al., 2000; Pruitt and Maglott,
2001) (Fig. 2, upper panel). Since the RTCG database already
contains about 2300 RISs, it was not foreseen that we from such
a small sample were able to identify 14 novel RISs (Table 1) and
furthermore define 9 novel CISs (Table 1). Some of the iden-
tified RISs may be “passenger integrations” that by chance have
been drawn into end-stage tumor cells, but play no role in the
oncogenic process (a feature that may as well apply to RISs al-
ready included in the RTCGD). However, since CISs define
regions or genes that are targeted by two or more viruses in
independent experiments, these regions most likely are of bio-
logical relevance and do contribute to induction or progression
of tumor development. Thus, altogether our findings strongly
emphasize the importance of the experimental model system.
As previously published, the N-ras/unr locus defines a CIS
within the Akv1–99 setting (Martin-Hernandez et al., 2001)
since two tags target this chromosomal region, and, in addition,
we have defined the Pvt-1 locus (downstream of c-myc, a
position classified as c-myc RIS within the RTCGD) as a CIS
within the Akv wt setting since two tags out of 28 could be
addressed to this locus (see Table 1).
Distinct regions of the target gene are hit by Akv wt, Akv1–99,
and SL3-3
The collection of Akv wt and Akv1–99 sequence tags
isolated from comparable experimental settings allowed us to
evaluate if a general difference in integration site position re-
lative to the targeted gene could be detected. Besides, we were
able to include in this analysis sequence tags isolated from SL3-
3-induced tumors from one of our early studies (Sorensen et al.,
1996) since those tumors were induced in the same host genetic
background (randomly bred NMRI mice) and the tags were
isolated by means of the exact same PCR method. In contrast to
Akv (and Akv1–99), SL3-3 induces primarily T-cell lympho-
mas with an average latency period of about 3 months in ran-tains a 99 bp tandem repeat in the U3 enhancer region, while Akv1–99 MLV
nhancer repeats consisting of 2 1/2 repeats (2 × 72 (=34 + 38) bp + 34 bp). Below
NMRI mice are given in parentheses. Curved lines indicate flanking cellular
tion sites. VP = virus-specific primer.
Fig. 2. Distribution of tag sequences. Upper panel lists the number of amplified tag sequences for each of the three viruses, while lower panel shows the distribution of
insertions for each virus in relation to the target RefSeq.
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iously reported (Sorensen et al., 1996), 38 tag sequences
(Table 1) were isolated from 20 tumors, and, of these, 32 tag
sequences could be located within ±100 kb of a RefSeq (Fig.
2, upper panel).
From the defined chromosomal position (UCSC Genome
Browser; mm6), we assigned each proviral insertion to either
upstream of (−100 to −2 kb; distance to RefSeq), promoter
(−2000 to +1; positions relative to transcription start site
(+1)), within or downstream of (<100 kb; distance to RefSeq)
the relevant RefSeq. Table 2 and Fig. 2 show the proportion
of the tags positioned within each of these four regions. For
the upstream region (2 < 100 kb), no clear difference between
the three viruses could be detected. The orientations of the
inserted proviruses in this region are more or less equally
distributed with approximately half of the proviruses located
in the same (+) and half of the proviruses located in opposite
(−) transcriptional orientation compared to that of the target
gene, regardless of injected virus. It thus appears that there is
no need for a specific orientation in this region, no matter the
virus type, possibly reflecting that transcriptional interference
is not a problem when the two promoters (provirus and target
gene) are located far apart.
Conversely, a remarkable difference can be observed within
the promoter region between the three viruses. Thus, more than
one fourth (9/32) of all SL3-3 integrations are located here, and
what is more, 7 of these (∼21.9%) are in (−) orientation (Fig. 2and Table 2). This is in sharp contrast to the Akv and Akv1–99
insertions of which 0 of 24 and 1 of 26, respectively, could be
detected in (−) orientation within this area. This striking
difference probably reflects an inherent constraint on individual
viral promoter/enhancer structures that makes them dependent
on optimal genomic positions and orientations to exert their
effect on target gene expression in the relevant cell type. In this
case, it suggests that insertion in (−) orientation into the
promoter region of the target gene by “enhancer activation”
would be a favorable mode of target gene regulation in SL3-3-
induced T-cell lymphomagenesis in NMRI mice. In contrast,
both Akv insertions and one of two Akv1–99 insertions are in
(+) orientation, suggesting the promoter/enhancer potential of
the Akv type viruses to go well with a “promoter activation” of
the target gene in MLV-induced B-cell lymphomagenesis in
NMRI mice, an implication of which adjusts to our previous
observation for the Akv1–99 activation of N-ras gene (Martin-
Hernandez et al., 2001). It should be pointed out that 2 of the 7
(−) SL3-3 insertions are within the c-myc locus, which might
bias the comparison analyses. However, even if just one c-myc
insertion is included, the difference would still be statistically
significant, at least for Akv wt versus SL3-3 (0/24 compared to
6/31 would result in a two-tailed p value of 0.0300).
The distribution of insertions within the target RefSeq (Fig.
2) does not reveal differences of statistical significance among
the three viruses. Yet, it might be worth to note that far the
majority of the Akv1–99 insertions (18/26, 69.2%) are located
Table 1
Positions of integrated proviruses in tumor DNA
Virus Seq IDa Chromosome Position (mm6) Gene/RefSeqb No. of hits in
RTCGD (mm6)
Novel RISsc Novel CISsd
Akv wt 2-5 1 132,881,030 Mdm4 (+) 0 RIS –
Akv wt 1-3 1 133,098,949 Plekha6 (= PEPP-3) (−) 0 RIS –
SL3-3 wt 02-1 1 133,949,450 Fmod/Btg2/Chit1 (−) 8 n.a. –
Akv wt 4-12 1 156,902,934 Ralgps2 (−) 2 – –
Akv wt 9-26 1 159,928,469 AK034159 (−) 0 RIS –
Akv wt 1-1 1 165,766,945 Cd3z (−) 0 RIS –
Akv 1–99 1-3 1 194,981,785 Cr2 (+) 2 – –
Akv 1–99 1-4 2 101,313,783 B230118H07Rik (+) 0 RIS –
SL3-3 wt 17-2 2 122,165,719 AA467197 (−) 1 n.a. -
Akv 1–99 10-26 2 173,721,423 Gnas (−) 1 – –
SL3-3 wt 07-1 3 9,143,234 Tpd52 (+) (>100 kb) 1 n.a. –
Akv 1–99 5-17 3 20,839,330 Tbl1xr1 (+) (>100 kb) 0 – –
SL3-3 wt 13-1 3 58,883,848 P2ry12 (−) 1 n.a. –
SL3-3 wt 10-2 3 90,102,894 AK041594 (−) 1 n.a. –
Akv 1–99 3-10 3 102,485,944 N-ras (∼unr) (+) 3 – –
SL3-3 wt 18-1 3 102,485,964 N-ras (+) n.a. –
Akv 1–99 11-28 3 102,486,727 N-ras (+) – –
Akv wt 5-13 3 103,218,858 Hipk1 (+) 0 RIS –
SL3-3 wt 17-1 3 144,091,065 Odf2l (+) 1 n.a. -
Akv 1–99 7-20 4 44,618,339 Pax5 (−) 2 – –
SL3-3 wt 15-3 4 52,927,479 Nipsnap3a (−) 1 n.a. –
Akv wt 2-7 4 56,982,962 Epb4.1l4b (+) 1 – CIS
SL3-3 wt 12-5 4 96,726,431 D90173 (NF1-A; E130114P18Rik) (−) 2 n.a. –
Akv 1–99 2-9 4 100,150,450 Jak1 (+) 2 – –
Akv 1–99 7-19 4 105,896,335 Ssbp3 (−) 2 – –
Akv wt 6-18 4 131,922,266 Fgr (+) 2 – –
Akv wt 8-22 4 139,825,491 Padi2 (−) 2 – –
SL3-3 wt 04-1 5 23,149,126 AK086301/6330412F12Rik (−) 1 n.a. –
Akv 1–99 2-6 5 64,839,365 BC013481 (−) 2 – –
Akv wt 8-24 5 74,669,619 Kdr (−) 7 – –
Akv wt 4-10 5 119,775,031 Ddx54 (−) 1 – CIS
SL3-3 wt 12-2 6 41,675,818 Prss2 (+) 1 n.a. –
SL3-3 wt 12-3 6 86,395,570 Dusp11 (+) 1 n.a. –
Akv 1–99 1-1 6 116,113,879 Raf1 (+) 1 – CIS
SL3-3 wt 10-1 6 144,865,648 Sox5 (+) 4 n.a. –
Akv wt 2-6 7 69,475,419 Ak006382 (−) 2 – –
Akv wt 6-21 7 74,634,596 Zfp29 (−) 0 RIS –
Akv 1–99 5-15 7 95,943,590 Inppl (−) 0 RIS –
Akv 1–99 3-11 7 110,370,642 Nucb2 (−) 0 RIS –
Akv wt 1-4 7 120,523,186 Sh2 bpsm1 (+) 1 – CIS
SL3-3 wt 12-1 7 131,765,141 AK078159/AK051763 (−) 1 n.a. –
Akv 1–99 8-21 8 83,925,100 Ier2 (−) 3 – –
Akv 1–99 2-7 9 57,262,218 AK053006 (+) 0 RIS –
SL3-3 wt 01-1 9 96,849,049 Ssb4 (−) 2 n.a. –
Akv 1–99 4-12 9 100,978,548 Pccb (+) 0 RIS –
Akv wt 3-8 9 121,926,128 Ccbp2 (−)/Cyp8b1 (+) 1 – CIS
Akv wt 9-27 10 21,185,871 AK012856/Hbs1l (+) [Myb] 1 [52] – –
SL3-3 wt 09-1 10 41,691,278 Cd164 (−) 1 n.a. –
SL3-3 wt 06-2 10 80,602,387 Tcfe2a (−) 7 n.a. –
SL3-3 wt 20-1 11 29,702,668 AK029918/4931440F15Rik (+) 2 n.a. –
Akv wt 8-23 11 100,671,988 Stat5a/Stat5b (+) 4 – –
Akv 1–99 2-8 11 102,575,214 Adam11 (−) 0 RIS –
SL3-3 wt 15-4 11 117,138,899 Sept9 (−) 7 n.a. –
Akv 1–99 7-18 11 120,534,360 Stra13 (−) 0 RIS –
Akv wt 4-11 12 51,703,465 2700097O09Rik (+) 1 – CIS
SL3-3 wt 15-2 12 70,432,665 Prkch (−) 1 n.a. –
SL3-3 wt 16-1 12 82,499,930 Jundm2 (+) 8 n.a. –
Akv 1–99 11-27 12 101,415,129 Vrk1 (+) 2 – –
Akv 1–99 13-30 13 37,334,967 B930013M22Rik (−) 2 – –
Akv wt 3-9 13 37,365,555 B930013M22Rik (−) – –
Akv 1–99 4-14 13 54,778,021 BC027057 (−) 2 – –
SL3-3 wt 14-1 13 79,617,853 Mef2c (−) 7 n.a. –
Akv wt 5-17 14 49,034,537 Skb1 (−) 0 RIS –
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Table 1 (continued)
Virus Seq IDa Chromosome Position (mm6) Gene/RefSeqb No. of hits in
RTCGD (mm6)
Novel RISsc Novel CISsd
SL3-3 wt 05-1 14 69,523,941 Lcp1 (−) 2 n.a. –
SL3-3 wt 05-2 15 61,996,257 c-myc (−) n.a. –
SL3-3 wt 13-2 15 61,996,365 c-myc (+) n.a. –
SL3-3 wt 03-1 15 61,996,932 c-myc (−) 64 n.a. –
Akv wt 5-15 15 62,195,134 Pvt-1 (Z11981) (+) – –
Akv wt 5-16 15 62,203,857 Pvt-1 (Z11981) (+) – –
Akv wt 10-28 15 84,363,174 Parvb (+) 2 – –
Akv wt 6-20 15 97,542,948 MGC47262 (+) (>100 kb) 1 – –
SL3-3 wt 17-3 16 31,418,851 Tfrc (−) 1 n.a. –
Akv 1–99 1-2 16 57,495,961 St3gal6 (−) 1 – CIS
SL3-3 wt 06-1 17 27,310,608 Pim1 (−) 31 n.a. –
SL3-3 wt 18-2 17 81,978,728 Zfp36l2 (−) 6 n.a. –
Akv 1–99 4-13 18 14,144,708 Zfp521 (+) – –
Akv 1–99 8-22 18 14,159,838 Zfp521 (−) 6 – –
Akv 1–99 12-29 18 65,540,431 Malt1 (+) (>100 kb) 1 – –
Akv 1–99 5-16 18 69,576,755 Tcf4 (+) 1 – CIS*
Akv 1–99 9-24 18 75,520,423 Dym (+) 3 – –
SL3-3 wt 14-3 18 80,830,796 NFATc1 (+) 5 n.a. –
Akv 1–99 8-23 19 5,833,850 Syvn1 (−) 1 – CIS
Akv wt 5-14 19 36,837,014 Hhex (−) 29 – –
SL3-3 wt 08-1 19 41,375,287 Frat1 (+) 11 n.a. –
SL3-3 wt 08-2 X 6,186,125 Hdac6 (+) 2 n.a. –
SL3-3 wt 02-2 X 6,255,235 2010001H14Rik (−) 2 n.a. –
SL3-3 wt 12-4 Maps at several positions – – – – –
Akv 1–99 9-25 Maps at several positions – – – – –
SL3-3 wt 07-2 Maps at several positions – – – – –
SL3-3 wt 14-2 Maps at several positions – – – – –
Akv wt 6-19 Maps to several locations – – – – –
Akv wt 10-29 Maps to several locations – – – – –
SL3-3 wt 11-1 No match – – – – –
Akv wt 1-2 No match – – – – –
SL3-3 wt 19-1 No match – – – – –
a Seq ID refers to tumor no.-seq no.; i.e. 2-5 refers to tumor no. 2-seq. no. 5 within the series in question (e.g. Akv wt).
b The gene (or RefSeq) closest to the integrated provirus is given (UCSC, mouse mm6 assembly). + or − indicates the transcriptional orientation of the integrated
provirus relative to that of the gene/RefSeq.
c For each Akv wt and Akv1–99 insertion, it is indicated, based on RTCGD (mm6), whether a novel RIS has been defined. – signifies that the gene/RefSeq is already
defined as a RIS/CIS in the database. n.a.; not applicable, refers to the fact that all SL3-3 insertions have already been included in RTCGD.
d For each Akv wt and Akv1–99 insertion, it is indicated, based on RTCGD (mm6), whether a novel CIS has been defined. The definition follows the
recommendations from RTCGDwith a window size of 100 kb, 50 kb, and 30 kb for CISs with 4 (or more), 3, or 2 insertions, respectively. * indicates an exception from
this rule since the two integration sites – separated by about 175 kb – were found within introns of the same gene, Tcf4.
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evenly dispersed over the four defined regions (Fig. 2). This
apparent Akv1–99 clustering within the target gene is furtherTable 2
Frequency of proviral insertions within defined genomic regions
Virus Upstream (2 < 100 kb) Promoter (position
−2000 to +1)
+ − + −
Akv wt 2/24 4/24 2/24 0/24
Akv1–99 3/26 2/26 1/26 1/26
SL3-3 wt 1/32 2/32 2/32 7/32
+ or − denotes the orientation of the integrated provirus relative to the target RefSeq.
within each series.
a The frequency of Akv1–99 insertions downstream of RefSeq (1/26) is statistically
from Fisher's Exact Test).
b This frequency is statistically different from the ones observed within Akv wt
Fisher's Exact Test).supported by the clear difference between Akv wt (7/24) and
Akv1–99 (1/26) insertions in the region downstream of the
target RefSeq (Fig. 2 and Table 2).Within RefSeq Downstream of RefSeq
(<100 kb)
+ − + −
3/24 6/24 5/24 2/24
8/26 10/26 0/26a 1/26a
b 6/32 8/32 2/32 4/32
The frequency is given by observed number/total number of provirus integration
different from what is observed for Akv wt (7/24) (two-tailed p value is 0.0210
and Akv1–99 (two-tailed p values are 0.0160 and 0.0629, respectively, from
Table 3
Distribution of enhancer structures in Akv wt and Akv1–99-induced lymphomas
Input virus Enhancer repeat structurea Upstream of RefSeq Promoter of RefSeq Within RefSeq Downstream of RefSeq Outsideb Total
Akv wt 1 × 99 bp 2 1 3 0 0 6
2 × 99 bp 1 0 4 2 1 8
Akv1–99 1 × 99 bp 1 1 11 0 2 15
2 × 99 bp 0 0 0 0 0 0
Upstream, Promoter, Within, and Downstream have been defined in Fig. 2 and Table 2.
a Enhancer repeat structures in end-stage tumors.
b “Outside” is more than 100 kb apart from the closest RefSeq (both up- and downstream).
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insertion within RefSeq
The tendency of Akv1–99 proviruses to cluster inside the
target gene may reflect that loss of one enhancer repeat would
influence the “favorable regions of insertions” with respect to
the provirus strength required to affect target gene expression
during the lymphomagenic process. In order to pursue this,
we analyzed the proviral enhancer structure of the individual
integrations in the Akv wt tumors. The 5′LTR enhancer was
PCR-amplified by a genomic primer (constructed in each case
from the specific integration site sequence; FP, Fig. 1) toge-
ther with a proviral-specific primer located in U3 downstream
of the enhancer region (VP, Fig. 1). Altogether, we amplified
14 integration sites, and in 6 of these, it turned out that exactly
one repeat had been lost (no other mutations were identified),
while in the remaining 8 cases the input 2 × 99 bp repeat was
retained (Table 3). However, irrespective of the number of
enhancer repeats recovered in the lymphoma tissues, half of the
insertions (3 out of 6 and 4 out of 8; Table 3) were located with-
in the RefSeq. Thus, the above notion about a possible corre-
lation between number of enhancer repeats and tendency to
cluster within the target gene could not be supported by this
kind of analysis. The enhancer repeat structures of the Akv1–
99 insertions were analyzed as well in 15 cases of which none
revealed any mutations (Table 3).
Conclusions
Several studies have focused on defining novel RISs and
CISs in MLV-induced cancers in mice (Erkeland et al., 2004;
Hansen et al., 2000; Johansson et al., 2004; Kim et al., 2003;
Li et al., 1999; Lund et al., 2002; Mikkers et al., 2002; Suzuki
et al., 2002), where the majority of the identified integration
sites are selected for during the tumorigenic process. Other
studies have dealt with the related theme of retroviral DNA
integration mechanisms and site preferences, where unselected
integration sites have been the subject of analyses. In the latter
case, it has been shown that avian sarcoma-leukosis virus
(ASLV), human immunodeficiency virus (HIV), and MLV
show distinct target site preferences, with MLV showing an
inclination to integrate near transcription start sites (Hematti et
al., 2004; Mitchell et al., 2004; Wu et al., 2003). It should be
noted, though, that MLV insertions in these cases are repre-
sented by infecting HeLa cells with pseudotyped Moloney
MLVs.In the present study, we have shown that, although MLVs
may reveal a general preference for specific insertion areas in
the process of integration, the picture might look quite different
after selection during a tumorigenic process. Different types of
MLV may in certain cell type contexts favor distinct genomic
regions and orientations to perform in an optimal way. Moreo-
ver, we have exposed clearly the importance of the experimental
model system (mouse strain and virus type) with respect to the
resulting RISs and CISs that are identified as putative cancer-
related genes in retroviral insertional mutagenesis studies in
mice.
Materials and methods
Origin of lymphomas and MLV types
Tumors originate from previous studies: Akv and Akv1–99-
induced tumors in randomly bred NMRI mice (Lovmand et al.,
1998) and SL3-3-induced tumors in randomly bred NMRI mice
(Hallberg et al., 1991; Sorensen et al., 1996).
Provirus integration site isolation
Genomic DNA was extracted from frozen tissues, and
provirus integration sites were amplified by a two-step PCR
method described previously (Sorensen et al., 1996; Sorensen et
al., 1993). The resulting PCR products were purified, and
sequences were determined by the use of ABI 7300 Biosystems.
Provirus integration site analysis
The sequence of each provirus integration site was compared
(BLAT search) to the UCSC Genome Browser, version mm6,
and in most cases the tag sequence displayed unambiguous
chromosomal position (see Fig. 2). Furthermore, to identify
possible novel provirus integration sites, the individual integ-
ration sites were concomitantly matched up to the Retroviral
Tagged Cancer Gene Database (RTCGD; http://RTCGD.ncifcrf.
gov; Akagi et al., 2004).
From the exact chromosomal position, each integration site
was – when possible – placed relative to a target gene/RefSeq;
either upstream of (−100 to −2 kb), within the promoter
(defined here as the 2 kb immediately upstream of the
transcription start site), within (within the boundaries of the
RefSeq), or downstream of (less than a distance of 100 kb) the
target Ref- Seq.
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The specific 5′LTR enhancer sequences from individual
provirus integration sites were amplified by PCR using a
virus-specific primer, VP: 5′-GGAACCTTGAGACAGTTT-
CTGGGTCT-3′ that is located in U3 downstream of the
enhancer region (position 333–358 in the Akv U3/LTR)
together with a specific flanking genomic primer (FP), con-
structed for every integration sites. Altogether, amplification
products were obtained and sequenced from 14 Akv wt
and 15 Akv1–99 integration sites, representing almost all
tumors.
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